# reload+after+2024-01-22 08:43:24.816774
address1§River Oaks Tower
address2§Suite 1200 3730 Kirby Drive
city§Houston
state§TX
zip§77098
country§United States
phone§936 355 1910
website§https://aravive.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.
fullTimeEmployees§23
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Fredric N. Eshelman Pharm.D.', 'age': 74, 'title': 'Executive Chairman', 'yearBorn': 1949, 'fiscalYear': 2022, 'totalPay': 95000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Gail F. McIntyre CH (ASCP), DABT, Ph.D.', 'age': 60, 'title': 'President, CEO & Director', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 803994, 'exercisedValue': 0, 'unexercisedValue': 32012}, {'maxAge': 1, 'name': 'Mr. Rudy C. Howard B.A., CPA', 'age': 65, 'title': 'Chief Financial Officer', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 500264, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jeffrey L. Cleland Ph.D.', 'age': 58, 'title': 'Co-Founder', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 669977, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Joshua Aaron Silverman Ph.D.', 'title': 'Co-Founder', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Marek  Ciszewski J.D.', 'title': 'Vice President of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§10
boardRisk§9
compensationRisk§8
shareHolderRightsRisk§8
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§2.186
priceToSalesTrailing12Months§1.272673
currency§USD
dateShortInterest§1702598400
forwardEps§-0.09
pegRatio§0.0
exchange§NMS
quoteType§EQUITY
shortName§Aravive, Inc.
longName§Aravive, Inc.
firstTradeDateEpochUtc§1395408600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§436420eb-ae2d-3616-84a1-4664b78d3c14
gmtOffSetMilliseconds§-18000000
targetHighPrice§0.25
targetLowPrice§0.25
targetMeanPrice§0.25
targetMedianPrice§0.25
recommendationMean§3.0
recommendationKey§hold
numberOfAnalystOpinions§1
quickRatio§0.873
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
